The present invention relates to compounds of formula (I) wherein R.sup.1, R.sup.2, R.sup.3 R.sup.3a and R.sup.3b are as provided in the description, and pharmaceutically acceptable salts thereof, for use in the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors such as obesity.